#36 In atrial fibrillation: rate versus rhythm and how slow do you go?
CLINICAL QUESTION
For patients with persistent atrial fibrillation (A Fib), how does medically attempting to restore/maintain sinus rhythm compare to rate control (and what should be the target heart rate)?
BOTTOM LINE
Patients with persistent Afib are more likely to benefit from rate control than rhythm control. Targeting resting heart rate to <80 does not appear necessary. Regardless of the treatment strategy, anti-thrombotic therapy is central to management.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Rate versus rhythm: Two latest meta-analyses1,2 of 10-13 Randomized Controlled Trials (RCTs) comparing pharmacological rate versus rhythm control in 7,867 patients:
- Statistically significantly fewer hospitalizations:1 50.8% versus 58.3%, Number Needed to Treat (NNT)=14.
- No difference in individual composite of embolic events, or individual outcomes of death, stroke or systemic embolism, worsening heart failure, or bleeding.1,2
- Similar quality of life.2
- Less likely to be in sinus rhythm (example from largest RCT:3 35% versus 63%).
- Composite outcome of cardiovascular, bleed, and hospitalization (12.9% versus 14.9% [hazard ratio 0.84 (90% CI 0.58 to 1.21)].
- Although historically it was thought attempting to restore sinus rhythm was advantageous, medications used to establish and maintain sinus rhythm have several risks.
- Even in patients with coexistent congestive heart failure and AFib, mortality and morbidity outcomes did not differ between rate and rhythm groups.5
- Canadian guidelines recommend:6
- Rate control for most patients;
- Select patients may benefit from rhythm control, e.g. highly symptomatic, quality of life impairment, multiple recurrences, arrhythmia-induced cardiomyopathy.
- Regardless of treatment strategy, antithrombotic therapy is central to AFib management.6
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
